Originally published by our sister publication Pharmacy Practice News
The Centers for Medicare & Medicaid Services (CMS) is seeking comment from the public about the Medicare Prescription Drug Inflation Rebate Program, which was designed to collect rebates from manufacturers who raise prescription drug prices faster than the rate of inflation.
CMS seeks comments about:
- the process to determine the number of drug units for rebatable drugs;
- reduction of rebate amounts for certain Part B and Part